Kisunla
-
Lilly’s Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer’s Disease
Congratulations to Eli Lilly and AD patients!
-
重磅快讯！礼来阿尔茨海默新药donanemab终于获批了！12个月疗程32,000美元
热烈祝贺礼来公司和阿尔茨海默病患者！
